Decline in Cosmetic Sales Affected Coty (COTY) in Q1
In its first-quarter 2025 investor letter, Hardman Johnston Global Equity Strategy highlighted stocks such as Coty Inc. (NYSE:COTY). Coty Inc. (NYSE:COTY) is a beauty company that engages in the manufacturing, marketing, and distribution of beauty products. The one-month return of Coty Inc. (NYSE:COTY) was -6.44%, and its shares lost 52.36% of their value over the last 52 weeks. On June 30, 2025, Coty Inc. (NYSE:COTY) stock closed at $4.65 per share, with a market capitalization of $4.056 billion.
Hardman Johnston Global Equity Strategy stated the following regarding Coty Inc. (NYSE:COTY) in its Q1 2025 investor letter:
"Coty Inc. (NYSE:COTY) has been impacted by the overall slowdown in cosmetic sales. They issued a sales warning in September, followed by a downward adjustment of mid-term targets in February. While Coty's products are selling well, retailer hesitancy to re-order and questions about consumers appetite have hit the stock. We used a period of relative strength to liquidate our position."
A close-up of a woman's face wearing a beauty product, highlighting the company's range of luxury items.
Coty Inc. (NYSE:COTY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held Coty Inc. (NYSE:COTY) at the end of the first quarter, which was 28 in the previous quarter. While we acknowledge the potential of Coty Inc. (NYSE:COTY) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.
In another article, we covered Coty Inc. (NYSE:COTY) and shared the list of best value penny stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of COTY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
HELOC rates today, August 13, 2025: Fees can be just important as your interest rate
HELOC rates today are still under 8.75%. When shopping for a home equity line of credit, fees can be just as important as your interest rate. Shop lenders and look for low — or better yet, zero — application, origination, and appraisal fees. Annual service fees should be avoided as well. Then, ask about the introductory rate and the variable rate you'll pay after the intro rate expires. Now, let's check today's home equity line of credit rate. Dig deeper: Is now a good time to take out a HELOC? HELOC rates Wednesday, August 13, 2025 According to Bank of America, the largest HELOC lender in the country, today's average APR on a 10-year draw HELOC remains 8.72%. That is a variable rate that kicks in after a six-month introductory APR, which is 6.49% in most parts of the country. The lowest HELOC rate reported was 8.05%, with the maximum 9.59%. Homeowners have a sizable amount of value tied up in their houses — more than $34 trillion at the end of 2024, according to the Federal Reserve. That's the third-largest amount of home equity on record. With mortgage rates lingering in the high 6% range, homeowners are not likely to let go of their primary mortgage anytime soon, so selling the house may not be an option. Why let go of your 5%, 4% — or even 3% mortgage? Accessing some of the value locked into your house with a use-it-as-you-need-it HELOC can be an excellent alternative. How lenders determine HELOC interest rates HELOC interest rates are different from primary mortgage rates. Second mortgage rates are based on an index rate plus a margin. That index is often the prime rate, which today is 7.50%. If a lender added 1% as a margin, the HELOC would have a rate of 8.50%. Lenders have flexibility with pricing on a second mortgage product, such as a HELOC or home equity loan, so it pays to shop around. Your rate will depend on your credit score, the amount of debt you carry, and the amount of your credit line compared to the value of your home. And average national HELOC rates can include "introductory" rates that may only last for six months or one year. After that, your interest rate will become adjustable, likely beginning at a substantially higher rate. How a HELOC works You don't have to give up your low-rate mortgage to access the equity in your home. Keep your primary mortgage and consider a second mortgage, such as a home equity line of credit. The best HELOC lenders offer low fees, a fixed-rate option, and generous credit lines. A HELOC allows you to easily use your home equity in any way and in any amount you choose, up to your credit line limit. Pull some out; pay it back. Repeat. Meanwhile, you're paying down your low-interest-rate primary mortgage like the wealth-building machine you are. Look for introductory rates, but be aware of a rate adjustment later Today, FourLeaf Credit Union is offering a HELOC rate of 6.49% for 12 months on lines up to $500,000. That's an introductory rate that will convert to a variable rate later. When shopping lenders, be aware of both rates. And as always, compare fees, repayment terms, and the minimum draw amount. The draw is the amount of money a lender requires you to initially take from your equity. The power of a HELOC is tapping only what you need and leaving some of your line of credit available for future needs. You don't pay interest on what you don't borrow. HELOC rates today: FAQs What is a good interest rate on a HELOC right now? Rates vary so much from one lender to the next that it's hard to pin down a magic number. You may see rates from nearly 7% to as much as 18%. It really depends on your creditworthiness and how diligent a shopper you are. Is it a good idea to get a HELOC right now? For homeowners with low primary mortgage rates and a chunk of equity in their house, it's probably one of the best times to get a HELOC. You don't give up that great mortgage rate, and you can use the cash drawn from your equity for things like home improvements, repairs, and upgrades. Of course, you can use a HELOC for fun things too, like a vacation — if you have the discipline to pay it off promptly. A vacation is likely not worth taking on long-term debt. What is the monthly payment on a $50,000 home equity line of credit? If you take out the full $50,000 from a line of credit on a $400,000 home, your payment may be around $395 per month with a variable interest rate beginning at 8.75%. That's for a HELOC with a 10-year draw period and a 20-year repayment period. That sounds good, but remember, it winds up being a 30-year loan. HELOCs are best if you borrow and pay back the balance in a much shorter period of time.
Yahoo
13 minutes ago
- Yahoo
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland and the US. At present, there are approximately 123 actively enrolling sites globally. According to the latest data collected by the European Cancer Information System (click here), a total of 12,861 new cases of breast cancer were diagnosed in Romania in 2022, which is the most common cancer diagnosed in women, representing approximately 28% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Romania with 3,877 deaths in 2022. The Company is collaborating with Dr. Nicoleta Antone, who is leading one of the largest academic breast cancer focused centers in Cluj Napoca, Romania, and her colleagues from at least 3 other sites in Romania. The Romanian clinical sites will be listed here with an interactive map. Dr. Antone will be serving as the national principal investigator in Romania for FLAMINGO-01. She is Head of Breast Cancer Centre at the Chiricuta Institute of Oncology in Cluj Napoca, Romania. She has been the Chair of the Romania Breast Cancer Group since 2021 and a member of the Women's Empowerment Cancer Advocacy Network since 2015. CEO Snehal Patel commented, "Romania is the first of several additional countries in Europe that we hope to add to Flamingo-01 as we now focus on mid-sized population countries with large population centers. We have visited the sites in Romania multiple times to assess study feasibility and provide training, and we are impressed with their facilities and commitment to the study. We look forward to working with Dr. Antone and her colleagues and have sufficiently advanced start-up activities this summer to be potentially screening and enrolling our first Romanian patients in the coming months." About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. For more information on FLAMINGO-01, please visit the Company's website here and here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@ About Breast Cancer and HER2/ Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at and follow the Company's Twitter at Forward-Looking Statement Disclaimer Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law. Company ContactSnehal PatelInvestor RelationsOffice: (832) 819-3232Email: info@ Investor & Public Relations Contact for Greenwich LifeSciencesDave GentryRedChip Companies 1-800-RED CHIP (733 2447)Email: dave@ in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
A Flash in the Pan: The Strange Story of Kodak's Ill-Fated Crypto Venture
Key Takeaways Eastman Kodak on Monday warned it could be forced to declare bankruptcy for the second time since 2012. Its last bankruptcy led the company to pursue licensing deals, one of which, in 2018, involved a blockchain-powered photo rights platform, KODAKOne, and associated cryptocurrency, KODAKCoin. KODAKCoin's private placements and initial coin offering, undertaken during 2018's crypto winter, were poorly received, and KODAKOne never launched in Kodak (KODK), after more than 100 years in business, may not be long for this world. The company issued a 'going concern' warning on Monday, informing investors it lacks the financing or adequate cash flow to pay debt that's coming due in the next 12 months. Kodak, once one of the largest companies in the world and a developer of cutting-edge technology, fell victim to the digitization of photography and, after years of declining sales, declared bankruptcy in 2012. It emerged from bankruptcy focused on printing technology and specialty chemicals while licensing its brand name on the side. That line of business roped it into a questionable venture in the world of cryptocurrency at what proved to be an inauspicious time. What Was KODAKOne? Kodak, in January 2018, announced a licensing agreement with the company WENN Digital, which agreed to launch KODAKOne, a platform through which photographers could use blockchain technology to manage and monetize their photos, and KODAKCoin, a native cryptocurrency. The platform was to be launched with the funds raised from a KODAKCoin initial coin offering, which began in May 2018. Kodak's licensing agreement reportedly gave it a minority stake in WENN Digital, 3% of all KodakCoins, and future royalties. The idea was that photographers would upload their photographs to KODAKOne, where they would license the images and use web-crawling software to flag copyright violations. Users would be paid in KODAKCoin for all business conducted on the platform. The rub: the KODAKCoin ICO, to comply with securities laws, was only open to accredited investors—anyone with a net worth of more than $1 million or annual income of $200,000 or more. So, photographers were to be paid in a cryptocurrency that could only be used to pay for services on the platform, which KODAKOne said would eventually include a marketplace for the sale and rental of equipment or studio space. But if they wanted to convert any of that KODAKCoin into dollars, they would need to find a rich person to buy it. That may not have been an issue if KODAKCoin took off in its ICO, but its reception was lukewarm at best. According to the project's confidential offering memorandum, which cryptocurrency blogger David Gerard acquired and published in the midst of the ICO, an early 2018 private placement raised just $880,000 of the $6.75 million that was expected. Bad Idea Meets Bad Timing Kodak's attempt to jump on the crypto train appeared fruitful at first. Shares tripled in value in the days after the January 8 announcement. Unfortunately for Kodak, its foray into digital assets coincided with the onset of crypto winter—the cyclical slump in crypto markets that tends to follow periods of speculative frenzy. The price of bitcoin slid from a record high of more than $20,000 in late 2017 to less than $4,000 in December 2018. In October 2018, KODAKOne launched a beta version of its licensing portal, which reportedly generated $1 million in licensing claims in its first two months. But the portal never exited beta mode, nor was KODAKCoin ever integrated with the platform. The last time Kodak mentioned the project was in August 2019, when it noted the volatility of the cryptocurrency market could pose a risk to its stock price. By the time of its third-quarter earnings report in November, crypto was no longer a risk. According to Gerber, KODAKOne's web domain was effectively shut down in late 2020. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
